Opinion
Video
Author(s):
A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.
Video content above is prompted by the following questions:
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity